Despite decades of research and the best up-to-date treatments, grade 4 Glioblastoma
(GBM) remains uniformly fatal with a patient median overall survival of less than 2 years …

Gliomas are highly treatment refractory against immune checkpoint blockade, an
immunotherapeutic modality that revolutionized therapy for many tumors. At the same time …

Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II
molecules is crucial for rational development of immunotherapies and vaccines targeting …

Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …

Liver metastases are associated with poor response to current pharmacological treatments,
including immunotherapy. We describe a lentiviral vector (LV) platform to selectively …

Tumor-associated neutrophil (TAN) effects on glioblastoma (GBM) biology remain under-
characterized. We show here that neutrophils with dendritic features—including …

Strategies to improve T cell therapy efficacy in solid tumors such as hepatocellular
carcinoma (HCC) are urgently needed. The common cytokine receptor γ chain (γc) family …

Although Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved in
multiple diseases, including BRCA1/2 mutant breast cancer, responses are usually transient …

Advances in mass spectrometry accelerates the characterization of HLA ligandome,
necessitating the development of efficient methods for immunopeptidomics analysis and …

Aims Glioblastoma is the most frequent and aggressive primary brain tumor, characterized
by rapid disease course and poor treatment responsiveness. The abundance of …